127 related articles for article (PubMed ID: 38088494)
21. Construction of a novel signature based on immune-related lncRNA to identify high and low risk pancreatic adenocarcinoma patients.
Li N; Chen J; Yu W; Huang X
BMC Gastroenterol; 2023 Sep; 23(1):312. PubMed ID: 37710166
[TBL] [Abstract][Full Text] [Related]
22. SQLE, A Key Enzyme in Cholesterol Metabolism, Correlates With Tumor Immune Infiltration and Immunotherapy Outcome of Pancreatic Adenocarcinoma.
You W; Ke J; Chen Y; Cai Z; Huang ZP; Hu P; Wu X
Front Immunol; 2022; 13():864244. PubMed ID: 35720314
[TBL] [Abstract][Full Text] [Related]
23. Development and validation of a hypoxia-stemness-based prognostic signature in pancreatic adenocarcinoma.
Tian X; Zheng J; Mou W; Lu G; Chen S; Du J; Zheng Y; Chen S; Shen B; Li J; Wang N
Front Pharmacol; 2022; 13():939542. PubMed ID: 35935823
[No Abstract] [Full Text] [Related]
24. CHST12: a potential prognostic biomarker related to the immunotherapy response in pancreatic adenocarcinoma.
Liu K; Li L; Han G
Front Endocrinol (Lausanne); 2023; 14():1226547. PubMed ID: 38333724
[TBL] [Abstract][Full Text] [Related]
25. A prospective prognostic signature for pancreatic adenocarcinoma based on ubiquitination-related mRNA-lncRNA with experimental validation in vitro and vivo.
Wang Z; Yuan Q; Chen X; Luo F; Shi X; Guo F; Ren J; Li S; Shang D
Funct Integr Genomics; 2023 Aug; 23(3):263. PubMed ID: 37540295
[TBL] [Abstract][Full Text] [Related]
26. Identification of the Real Hub Gene and Construction of a Novel Prognostic Signature for Pancreatic Adenocarcinoma Based on the Weighted Gene Co-expression Network Analysis and Least Absolute Shrinkage and Selection Operator Algorithms.
Yuan Q; Ren J; Wang Z; Ji L; Deng D; Shang D
Front Genet; 2021; 12():692953. PubMed ID: 34490033
[No Abstract] [Full Text] [Related]
27. Ferroptosis-related genes prognostic signature for pancreatic cancer and immune infiltration: potential biomarkers for predicting overall survival.
Wang L; Wu Z; Xu C; Ye H
J Cancer Res Clin Oncol; 2023 Dec; 149(20):18119-18134. PubMed ID: 38007403
[TBL] [Abstract][Full Text] [Related]
28. Mitochondrial energy metabolism-related gene signature as a prognostic indicator for pancreatic adenocarcinoma.
Ma Y; Tang R; Huang P; Li D; Liao M; Gao S
Front Pharmacol; 2024; 15():1332042. PubMed ID: 38572434
[No Abstract] [Full Text] [Related]
29. EIF2Ss, a Novel c-Myc-Correlated Gene Family, is Associated with Poor Prognosis and Immune Infiltration in Pancreatic Adenocarcinoma.
Cao Z; Jing Y; Cheng C; Wang F; Guan M; Zhang K; Jiao J; Ruan L; Chen Z
Front Biosci (Landmark Ed); 2024 Mar; 29(3):119. PubMed ID: 38538250
[TBL] [Abstract][Full Text] [Related]
30. Construction and comprehensive analysis of a novel prognostic signature associated with pyroptosis molecular subtypes in patients with pancreatic adenocarcinoma.
Huang Q; Peng X; Li Q; Zhu J; Xue J; Jiang H
Front Immunol; 2023; 14():1111494. PubMed ID: 36817451
[TBL] [Abstract][Full Text] [Related]
31. High expression of LAMA3/AC245041.2 gene pair associated with KRAS mutation and poor survival in pancreatic adenocarcinoma: a comprehensive TCGA analysis.
Tian C; Li X; Ge C
Mol Med; 2021 Jun; 27(1):62. PubMed ID: 34134622
[TBL] [Abstract][Full Text] [Related]
32. Determination of a DNA repair-related gene signature with potential implications for prognosis and therapeutic response in pancreatic adenocarcinoma.
Lai J; Chen W; Zhao A; Huang J
Front Oncol; 2022; 12():939891. PubMed ID: 36353555
[TBL] [Abstract][Full Text] [Related]
33. Development and validation of a novel glycolysis-related risk signature for predicting survival in pancreatic adenocarcinoma.
Li A; Hou S; Chen J; Jiang Y
Clin Chim Acta; 2021 Jul; 518():156-161. PubMed ID: 33775699
[TBL] [Abstract][Full Text] [Related]
34. An epithelial-mesenchymal transition-related mRNA signature associated with the prognosis, immune infiltration and therapeutic response of colon adenocarcinoma.
Zhang Y; Li Y; Zuo Z; Li T; An Y; Zhang W
Pathol Oncol Res; 2023; 29():1611016. PubMed ID: 36910014
[No Abstract] [Full Text] [Related]
35. Construction and Validation of an Immune-Based Prognostic Model for Pancreatic Adenocarcinoma Based on Public Databases.
Mao M; Ling H; Lin Y; Chen Y; Xu B; Zheng R
Front Genet; 2021; 12():702102. PubMed ID: 34335699
[TBL] [Abstract][Full Text] [Related]
36. Gene coexpression network approach to develop an immune prognostic model for pancreatic adenocarcinoma.
Gu X; Zhang Q; Wu X; Fan Y; Qian J
World J Surg Oncol; 2021 Apr; 19(1):112. PubMed ID: 33845841
[TBL] [Abstract][Full Text] [Related]
37. Identification of Prognostic Immune-Related Genes in Pancreatic Adenocarcinoma and Establishment of a Prognostic Nomogram: A Bioinformatic Study.
Wu G; Deng Z; Jin Z; Wang J; Xu B; Zeng J; Peng M; Wen Z; Guo Y
Biomed Res Int; 2020; 2020():1346045. PubMed ID: 32596278
[TBL] [Abstract][Full Text] [Related]
38. Development and validation of a novel N6-methyladenosine (m6A)-related multi- long non-coding RNA (lncRNA) prognostic signature in pancreatic adenocarcinoma.
Yuan Q; Ren J; Li L; Li S; Xiang K; Shang D
Bioengineered; 2021 Dec; 12(1):2432-2448. PubMed ID: 34233576
[TBL] [Abstract][Full Text] [Related]
39. A Risk Model for Prognosis and Treatment Response Prediction in Colon Adenocarcinoma Based on Genes Associated with the Characteristics of the Epithelial-Mesenchymal Transition.
Huang H; Li T; Meng Z; Zhang X; Jiang S; Suo M; Li N
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686013
[TBL] [Abstract][Full Text] [Related]
40. Machine Learning Developed a MYC Expression Feature-Based Signature for Predicting Prognosis and Chemoresistance in Pancreatic Adenocarcinoma.
Dong B; Zhang Y; Gao H; Liu J; Li J
Biochem Genet; 2024 Jan; ():. PubMed ID: 38245886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
